. Author manuscript; available in PMC: 2019 Apr 1.

Published in final edited form as: Hepatology. 2018 Apr;67(4):1560–1599. doi: 10.1002/hep.29800

Table 9.

Factors Influencing the Choice of Prophylaxis of HBsAg-Positive Liver Transplant Recipients

	Long-term HBIG Plus Indefinite NAs	Perioperative Only or No HBIG Plus Indefinite NAs
Patient Factors	Questionable adherence	Adherent High share of cost for medications
Virologic Factors	Presence of drug resistance or HBV DNA detectable at time of LT HIV coinfection HDV coinfection	No drug-resistant variants Undetectable to low (<100 IU/mL) HBV DNA at time of LT Absence of HIV and HDV coinfection
Other	Access to HBIG Lack access to entecavir or tenofovir (TDF or TAF)	Access to entecavir or tenofovir (TDF or TAF)

NA: nucleos(t)ide analogues; HBIG: hepatitis B immune globulin; TDF: Tenofovir dipovoxil fumarate; TAF: tenofovir alafenamide; LT: liver transplant; HIV: human immunodeficiency virus; HDV: hepatitis D virus